Clinical study of Tongluo-Qubai Decoction combined with routine western medicine therapy in the treatment of proteinuria in chronic glomerulonephritis with renal collaterals unsmooth / 国际中医中药杂志

ABSTRACT

Objective:To evaluate the clinical effect of Tongluo-Qubai Decoction combined with conventional western medicine on proteinuria of chronic glomerulonephritis (CGN) with renal collaterals unsmooth. Methods:124 patients with CGN proteinuria who met the inclusion criteria from January 2016 to December 2018 were randomly divided into two groups, 62 in each group. The control group took irbesartan tablets and dipyridamole tablets on the basis of conventional western medicine treatment; the observation group took Tongluo-Qubai Decoction on the basis of the control group. Both groups were treated for 3 months. The level of 24 h urinary protein quantification (24 h-Upro) was detected by immunoturbidimetry; plasma viscosity (PV) and TG were detected by automatic biochemical analyzer; to evaluate clinical therapeutic effect and TCM syndrome effect. Results:The total effective rate was 96.5% (60/62) in the observation group and 83.9% (52/62) in the control group. The total effective rate of TCM syndromes in the observation group was 90.3% (56/62) and that of the control group was 79.0% (49/62). The difference between the two groups was statistically significant ( χ2=10.301, P=0.040). After the treatment, 24 h-Upro (1.00 ± 0.65 g vs. 1.48 ± 0.71 g, t=4.998), PV (1.46 ± 0.30 mPa?s vs. 2.27 ± 0.28 mPa?s, t=6.292), TG (2.18 ± 0.68 mmol/L vs. 2.57 ± 0.73 mmol/L, t=7.025) in the observation group were lower than those of the control group ( P<0.01). Conclusions:Tongluo-Qubai Decoction combined with conventional western medicine can effectively improve the clinical symptoms of CGN proteinuria patients.